Objective To investigate the effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein on the clinical outcome of patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt( TIPS). Methods A retrospective analysis was performed for the clinical data of 120 patients with cirrhotic portal hypertension who underwent TIPS in The General Hospital of Western Theater Command from March 2016 to December 2019,and according to the target position of portal vein puncture determined by intraoperative angiography,the patients were divided into left branch group and right branch group.The two groups were compared in terms of the incidence rates of postoperative recurrence and bleeding,stent dysfunction,and hepatic encephalopathy( HE) and survival. The t-test was used for comparison of continuous data between two groups,and the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier curve was used to calculate rebleeding rate,stent patency rate,incidence rate of HE,and survival rate. Results The surgical success rate was 100% for all 120 patients,with a short-term hemostasis rate of100%. Among the 120 patients,52 underwent shunting of the left branch of the portal vein and 68 underwent shunting of the right branch.There was a significant reduction in portal venous pressure after surgery( 9. 98 ± 2. 84 mm Hg vs 24. 72 ± 5. 11 mm Hg,t = 37. 76,P < 0. 01).The cumulative rebleeding rates at 12 and 24 months after surgery were 3. 2% and 11. 0%,respectively,and the cumulative incidence rates of HE at 3,6,12,and 24 months after surgery were 10. 8%,13. 6%,21. 2%,and 24. 5%,respectively. Among the 29 patients who experienced HE,23 had gradeⅠ-ⅡHE and 6 had grade Ⅲ HE. The cumulative incidence rates of stent dysfunction at 12 and 24 months after surgery were 7. 1% and 21. 4%,respectively. The cumulative survival rates at 12 and 24 months after surgery were 92. 0% and 86. 5%,respectively.As for comparison of the left branch group and the right branch group,there were no significant differences in postoperative stent patency rate,rebleeding rate,incidence rate of HE,and survival rate( all P < 0. 05). Conclusion TIPS is a safe and effective method for the treatment of cirrhotic portal hypertension,and intraoperative Viatorr stent implantation,no matter for establishing the shunt of the left or right branch of the portal vein,will not affect the clinical outcome of patients.
[1] MALK J,HOLAJ R,KRUPICˇKOVZ,et al. Arteriovenous fistula after femoral artery puncture leading to pulmonary edema:The role of ultrasonography[J]. Prague Med Rep,2012,113(1):49-52.
|
[2] CASTILLO-SANG M,TSANG AW,ALMAROOF B,et al. Femoral artery complications after cardiac catheterization:A study of patient profile[J]. Ann Vasc Surg,2010,24(3):328-335.
|
[3] QIN JP,TANG W,TANG SH,et al. Modifiedtransjugular intrahepatic portosystemic shunt in the treatment of portal hypertemion of liver cirrhosis[J]. Chin J Dig,2014,34(1):33-36.(in Chinese)秦建平,唐文,汤善宏,等.改良经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症[J].中华消化学杂志,2014,34(1):33-36.
|
[4] YAO X,ZHOU H,TANG SH,et al. Stent dysfunction after transjugular intrahepatic portosystemic stent:Causes and countermeasures[J]. J Clin Hepatol,2019,35(5):1052-1056.(in Chinese)姚欣,周昊,汤善宏,等.经颈静脉肝内门体分流术后支架功能障碍的原因分析及处理策略[J].临床肝胆病杂志,2019,35(5):1052-1056.
|
[5] Interventional Group,Chinese Society of Radiology,Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组.经颈静脉肝内门体分流术专家共识[J].临床肝胆病杂志,2017,33(7):1218-1228.
|
[6] The Chinese College of Interventionalists. CCI clinical practice guidelines:Management of TIPS for portal hypertension(2019edition)[J]. J Clin Hepatol,2019,35(12):2694-2699.(in Chinese)中国医师协会介入医师分会.中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2694-2699.
|
[7] Group of Gastrointestinal Intervention,Chinese Society of Gastroenterology, Chinese Medical Association. Consensus on transjugular intrahepatic portosystemic shunt for treatment of cirrhotic portal hypertension[J]. J Clin Hepatol,2014,30(3):210-213.(in Chinese)中华医学会消化病学分会消化介入学组.经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压共识意见[J].临床肝胆病杂志,2014,30(3):210-213.
|
[8] THOMAS DB,HASKAL ZJ. The role of transjugular intrahepatic portosystemic shunt(TIPS)in the management of portal hypertension:Update 2009[J]. Hepatology,2010,51(1):386-400.
|
[9] QIN JP,TANG SH,JIANG MD,et al. Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning[J]. World J Gastroenterol,2015,21(32):9623-9629.
|
[10] TANG SH,QIN JP,JIANG MD,et al. The agreement and clinical value of hepatic vein pressure gradient and portal vein pressure in patients with portal hypertension[J]. Chin J Hepatol,2015,23(5):354-357.(in Chinese)汤善宏,秦建平,蒋明德,等.门静脉高压患者肝静脉压力梯度与门静脉压相关性及其临床价值[J].中华肝脏病杂志,2015,23(5):354-357.
|
[11] TRIPATHI D,STANLEY AJ,HAYES PC,et al. U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut,2015,64(11):1680-1704.
|
[12] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol,2017,10(33):1847-1863.(in Chinese)中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志,2017,10(33):1847-1863.
|
[13] BERCU ZL,FISCHMAN AM,KIM E,et al. TIPS for refractory ascites:A 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts[J]. AJR Am J Roentgenol,2015,204(3):654-661.
|
[14] CHU JG,SUN XL,PIAO LS,et al. Portosystemic shunt via left branch of portal vein for the prevention of encephalopathy following transjugular intrahepatic portosystemic shunt[J]. Chin J Hepatol,2002,10(6):437-440.(in Chinese)褚建国,孙晓丽,朴龙松,等.门静脉左支分流降低术后肝性脑病的临床研究[J].中华肝脏病杂志,2002,10(6):437-440.
|
[15] MOGICATO G,VAUTAVERS G,MEYNAUD-COLLARD P,et al. Blood flows in tributaries of the portal vein:Anatomical andangiographic studies in normal beagle dogs[J]. Anat Histol Embryol,2015,44(6):460-467.
|
[16] LJUBICIC N,DUVNJAK M,ROTKVIC I,et al. Influence of the degree of liver failure on portal blood flow in patientswith liver cirrhosis[J]. Scand J Gastroenterol,1990,25(4):395-400.
|
[17] QIN JP,JIANG MD,TANG W,et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis:A single center[J]. World J Gastroenter,2013,19(44):8085-8092.
|
[18] CHARON JP,ALAEDDIN FH,PIMPALWAR SA,et al. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol,2004,15(11):1219-1230.
|
[19] VIGNALI C,BARGELLINI I,GROSSO M,et al. TIPS with expanded polytetrafluoroethylene-covered stent:Results of an Italian multicenter study[J]. AJR Am J Roentgenol,2005,185(2):472-480.
|
[20] ANGELONI S,MERLI M,SALVATORI FM,et al. Polytetrafluoroethylene-covered stent grafts for TIPS procedure:1-year patency and clinical results[J]. Am J Gastroenterol,2004,99(2):280-285.
|
[21] DARCY M. Evaluation and management of transjugularintra hepatic portosystemic shunts[J]. Am J Roentgenol,2012,199(4):730-736.
|
[22] SAAD WE,DARWISH WM,DAVIES MG,et al. Stent-grafts for transjugular intrahepatic portosystemic shunt creation:Specialized TIPS stent-graft versus generic stent-graft/bare stent combination[J]. J Vasc Interv Radiol,2010,21(10):1512-1520.
|